Brokerages Set Maze Therapeutics, Inc. (NASDAQ:MAZE) Price Target at $66.00

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) have been assigned a consensus recommendation of “Buy” from the eleven ratings firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $66.00.

Several equities analysts recently commented on MAZE shares. HC Wainwright upped their price target on shares of Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. JPMorgan Chase & Co. lifted their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a report on Tuesday, March 31st. Wall Street Zen raised shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. BTIG Research restated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, March 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th.

Insider Buying and Selling at Maze Therapeutics

In other news, CEO Jason V. Coloma sold 34,501 shares of Maze Therapeutics stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $29.98, for a total value of $1,034,339.98. Following the transaction, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at $699,643.26. The trade was a 59.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $28.02, for a total value of $210,150.00. Following the sale, the insider owned 26,250 shares of the company’s stock, valued at $735,525. The trade was a 22.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 141,470 shares of company stock valued at $3,887,939. Company insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics during the 4th quarter valued at $39,000. Ameritas Investment Partners Inc. lifted its holdings in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in Maze Therapeutics during the 4th quarter worth $43,000. Finally, Russell Investments Group Ltd. boosted its position in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares during the period.

Maze Therapeutics Stock Up 0.9%

MAZE opened at $28.37 on Friday. Maze Therapeutics has a 12 month low of $12.81 and a 12 month high of $53.65. The business has a 50-day moving average of $26.93 and a two-hundred day moving average of $34.77. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -11.21 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. On average, research analysts expect that Maze Therapeutics will post -2.73 earnings per share for the current year.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.